BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,000 | +33.3% | 3,400 | 0.0% | 0.00% | – |
| Q3 2019 | $3,000 | -40.0% | 3,400 | 0.0% | 0.00% | – |
| Q2 2019 | $5,000 | -54.5% | 3,400 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $11,000 | +22.2% | 3,400 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $9,000 | -55.0% | 3,400 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $20,000 | -20.0% | 3,400 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $25,000 | +13.6% | 3,400 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $22,000 | -71.1% | 3,400 | -75.5% | 0.00% | -33.3% |
| Q4 2017 | $76,000 | -69.4% | 13,878 | -88.5% | 0.00% | -66.7% |
| Q3 2017 | $248,000 | +4.6% | 120,615 | +4.3% | 0.01% | 0.0% |
| Q2 2017 | $237,000 | +17.3% | 115,682 | +180.1% | 0.01% | +12.5% |
| Q1 2017 | $202,000 | +573.3% | 41,302 | +192.9% | 0.01% | +700.0% |
| Q4 2016 | $30,000 | -69.1% | 14,100 | +9.3% | 0.00% | -75.0% |
| Q3 2016 | $97,000 | +6.6% | 12,900 | -43.4% | 0.00% | 0.0% |
| Q2 2016 | $91,000 | -59.9% | 22,781 | -38.5% | 0.00% | -71.4% |
| Q1 2016 | $227,000 | -48.4% | 37,021 | -34.7% | 0.01% | -44.0% |
| Q4 2015 | $440,000 | – | 56,721 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 1,051,441 | $7,760,000 | 1.61% |
| X-Square Capital, LLC | 102,832 | $759,000 | 0.57% |
| CORRADO ADVISORS, LLC | 78,945 | $582,000 | 0.35% |
| Endurant Capital Management LP | 71,801 | $530,000 | 0.23% |
| Baker Brothers Advisors | 4,093,447 | $30,210,000 | 0.23% |
| KNOTT DAVID M | 76,653 | $566,000 | 0.21% |
| L & S Advisors Inc | 83,125 | $613,000 | 0.10% |
| DAFNA Capital Management LLC | 30,000 | $221,000 | 0.10% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,000,000 | $14,760,000 | 0.09% |
| HARVEY CAPITAL MANAGEMENT INC | 31,200 | $230,000 | 0.09% |